Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients

Stanford University

Status and phase: Not yet enrolling; Phase 2

Conditions: Kidney Transplantation; Hypophosphatemia

Treatments: Drug: Dipyridamole 75 MG

Study type: Interventional

Funder types: Other

Identifiers

NCT06824454

76830

Details and patient eligibility

About

The primary goal is to determine if Dipyridamole can improve serum phosphate levels and reduce the need for phosphate supplementation.

Enrollment: 90 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult kidney transplant patients.
• No known contraindications to Dipyridamole

Exclusion criteria

• Contraindications to Dipyridamole.
• Patients with delayed graft function (defined as the need for dialysis within seven days post-transplantation).
• Patients requiring Plavix, direct oral anticoagulants (DOACs), or Coumadin.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

90 participants in 2 patient groups

Treatment Group

Experimental group

Description:

Participants receive Dipyridamole in addition to standard post-transplant care.

Treatment:

Drug: Dipyridamole 75 MG

Control Group

No Intervention group

Description:

Participants in this group will receive standard post-transplant care without Dipyridamole.